Skip to main content

Thiogenesis Therapeutics Corp(TTI-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.510
Day High0.530
Open:0.530
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Thiogenesis Therapeutics Corp

Select a category then submit the form to load news
Newsfile
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update
Newsfile
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
Newsfile
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
Newsfile
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
GlobeNewswire
Thiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11th
Newsfile
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
Newsfile
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
Newsfile
Thiogenesis Announces Extension to Investor Relations Agreement
Newsfile
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update
Newsfile
Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares
Newsfile
Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares
Newsfile
Thiogenesis Upsizes Fully Subscribed Non-Brokered Private Placement of Common Shares
Newsfile
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
Newsfile
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
Newsfile
Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference
Newsfile
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
Newsfile
Thiogenesis Announces Grant of Stock Options
Newsfile
Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum
Newsfile
Thiogenesis Initiates Phase 2 Clinical Trial in Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS")
Newsfile
Thiogenesis Announces European Consulting and Investor Relations Agreement
Newsfile
Thiogenesis Announces Commencement of OTCQX Trading in the U.S.
Newsfile
Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
AI-generated - The Globe and Mail
Thiogenesis Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (TTI)
Newsfile
Thiogenesis Announces Presentation on UMDF Webcast Featuring Clinical Trials in Mitochondrial Disease
Newsfile
Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates
AI-generated - The Globe and Mail
Thiogenesis Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (TTI)
Newsfile
Thiogenesis Announces Important Core Patent Allowed in Europe
AI-generated - The Globe and Mail
Thiogenesis Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (TTI)
Newsfile
Thiogenesis Announces Investor Relations Engagement
Newsfile
Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium
Newsfile
Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program

Profile

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.